Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXTRIPHYLLINE vs AEROLATE SR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Xanthine derivative that inhibits phosphodiesterase, increasing intracellular cyclic AMP; also antagonizes adenosine receptors, leading to bronchodilation and stimulation of respiratory drive.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
Treatment of bronchial asthma,Chronic bronchitis,Pulmonary emphysema,Apnea of prematurity (off-label)
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
200 mg orally every 6 hours, or 400 mg orally every 8-12 hours; maximum 600 mg per dose.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
Adults: 3-5 hours (non-smokers); smokers: 4-6 hours; children: 1-4 hours; neonates: 20-30 hours; congestive heart failure or hepatic cirrhosis: prolonged up to 10-20 hours. Note: Oxtriphylline is a choline salt of theophylline, and its half-life reflects theophylline kinetics.
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Hepatic via CYP1A2 and CYP2E1; exhibits nonlinear pharmacokinetics at high doses.
Primarily hepatic via cytochrome P450 enzymes (CYP1A2, CYP2E1, and CYP3A4). Theophylline is metabolized to 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine.
Renal: ~70-80% as unchanged drug and metabolites (including theophylline); biliary/fecal: minimal (<10%)
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
Approximately 40-60% bound to plasma albumin; decreases in neonates and patients with hepatic disease
55–65% bound to plasma proteins, primarily albumin.
0.45-0.7 L/kg; approximates total body water; increased in premature infants (0.8-1.0 L/kg) and in cirrhosis
0.4–0.6 L/kg, indicating distribution into total body water.
Oral: 100%; rectal: >90%
Oral: 90–100% for sustained-release formulation; food decreases rate but not extent (AUC unchanged).
For GFR 30-50 m L/min: reduce dose by 50% and extend interval to every 8-12 hours. For GFR <30 m L/min: avoid use or reduce to 200 mg every 12 hours with close monitoring.
No dose adjustment required for renal impairment.
Child-Pugh A: no adjustment needed. Child-Pugh B: reduce dose by 50% and monitor levels. Child-Pugh C: contraindicated or use with extreme caution, maximum 200 mg every 12 hours.
Use with caution in severe hepatic impairment (Child-Pugh class C); consider dose reduction by 50%.
For children >1 year: 5 mg/kg orally every 6 hours; maximum 200 mg per dose. For infants 6-12 months: 4 mg/kg every 8 hours. Not recommended for neonates.
Children 6-12 years: 200-400 mcg inhaled twice daily. Children over 12 years: same as adult dose.
Initiate at 200 mg orally every 8-12 hours; titrate slowly, monitor for CNS excitation and arrhythmias. Use lower end of dosing range due to reduced clearance.
Start at lower end of dosing range (400 mcg twice daily) and titrate to response; monitor for systemic effects.
None.
No FDA black box warning exists for this drug.
Seizures: Risk increases with high serum levels (particularly >20 mcg/m L) and in patients with preexisting seizure disorders.,Cardiotoxicity: Includes ventricular arrhythmias and atrial fibrillation; risk increased with underlying cardiac disease or hypoxemia.,Gastrointestinal effects: Nausea, vomiting, and diarrhea are common; may indicate toxicity.
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Toxicity can include seizures, cardiac arrhythmias, and death. Caution in patients with heart failure, hepatic impairment, or those over 55 years. Risk of toxicity increased by concurrent medications such as cimetidine, fluoroquinolones, and macrolides.
Hypersensitivity to oxitriphylline or any xanthine derivative,Acute myocardial infarction,Uncontrolled arrhythmias,Preexisting seizure disorder (relative)
Hypersensitivity to theophylline or any component of the formulation; active seizure disorder; untreated cardiac arrhythmias; severe hypertension; hyperthyroidism; peptic ulcer disease; caution with concurrent use of ephedrine or other sympathomimetics.
Avoid or limit high-caffeine foods and beverages (coffee, tea, chocolate, cola) as they may potentiate side effects. Also avoid chargrilled meats and cruciferous vegetables (e.g., broccoli, cabbage) as they may alter theophylline metabolism.
High-fat meals may delay absorption. Avoid charcoal-grilled foods and large amounts of caffeine. Grapefruit juice may increase theophylline levels; limit intake.
Pregnancy Category C. No well-controlled studies in humans. Animal studies have shown adverse effects (fetal resorption, skeletal anomalies) at high doses. Risk cannot be ruled out; use only if clearly needed. First trimester: potential for teratogenicity based on animal data. Second/third trimesters: potential for respiratory alkalosis and electrolyte disturbances in fetus due to maternal alkalosis; avoid near term as may cause fetal tachycardia.
Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and reduced uterine contractility; avoid use near term due to potential for neonatal bradycardia and hypoglycemia.
Excreted into breast milk in small amounts. M/P ratio not determined. Use with caution; monitor infant for irritability, insomnia, and jitteriness. American Academy of Pediatrics considers compatible with breastfeeding, but preferable to use lowest effective dose.
Salbutamol is excreted into breast milk in minimal amounts; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. M/P ratio not established. Use with caution.
Pregnancy decreases theophylline clearance by approximately 20-30% due to reduced hepatic metabolism and increased volume of distribution. Dose reduction may be required to achieve therapeutic levels; monitor serum levels frequently. Avoid loading doses in early labor due to prolonged half-life.
No dose adjustment required for inhaled salbutamol. Increased clearance in late pregnancy may necessitate higher doses for systemic effects; monitor clinical response and adjust accordingly.
Oxtriphylline is a bronchodilator (xanthine derivative) with similar efficacy to theophylline. Monitor serum theophylline levels (target 5-15 mcg/m L) due to narrow therapeutic index. Caution in hepatic impairment, heart failure, and elderly. Drug interactions include CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) and inducers (e.g., carbamazepine, rifampin). Avoid rapid IV administration to prevent hypotension and arrhythmias.
AEROLATE SR contains theophylline; narrow therapeutic index (10-20 mcg/m L). Monitor serum levels, especially with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) or inducers (e.g., carbamazepine, phenytoin). SR formulation avoids peak-trough fluctuations; do not crush or chew. Caution in heart failure, hepatic impairment, and elderly.
Take exactly as prescribed; do not crush or chew enteric-coated tablets.,Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, or seizures.,Do not stop abruptly; taper under medical supervision.,Keep a diary of peak flow readings if used for asthma.
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Do not stop suddenly; sudden withdrawal may worsen breathing.,Avoid excessive caffeine (coffee, tea, chocolate) as it may increase side effects.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Keep regular appointments for blood level monitoring.
"Oxtriphylline, a xanthine derivative, is a prodrug of theophylline and is primarily metabolized by hepatic cytochrome P450 enzymes, notably CYP1A2 and CYP3A4. Nevirapine, a non-nucleoside reverse transcriptase inhibitor, induces CYP3A4 and other metabolic enzymes, potentially increasing the clearance of oxtriphylline's active metabolite theophylline. This reduction in theophylline exposure may decrease its bronchodilator efficacy, leading to worsening of respiratory symptoms in patients with asthma or COPD."
"Oxtriphylline, a xanthine bronchodilator, is metabolized primarily by CYP1A2 and CYP3A4. Azithromycin, a macrolide antibiotic, can inhibit CYP3A4, leading to decreased clearance of oxtriphylline and increased plasma concentrations. This may result in dose-related toxicity, including nausea, vomiting, tachycardia, and seizures."
"Oxtriphylline, a xanthine derivative used as a bronchodilator, may inhibit the metabolism of abiraterone, a CYP3A4 substrate, leading to increased serum concentrations of abiraterone. This elevation can potentiate the risk of abiraterone-related adverse effects such as hepatotoxicity, hypertension, hypokalemia, and fluid retention. Additionally, Oxtriphylline's own clearance may be affected, increasing the likelihood of xanthine toxicity manifesting as nausea, vomiting, or cardiac arrhythmias."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXTRIPHYLLINE vs AEROLATE SR, answered by our medical review team.
OXTRIPHYLLINE is a Bronchodilator that works by Xanthine derivative that inhibits phosphodiesterase, increasing intracellular cyclic AMP; also antagonizes adenosine receptors, leading to bronchodilation and stimulation of respiratory drive.. AEROLATE SR is a Bronchodilator that works by AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXTRIPHYLLINE and AEROLATE SR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXTRIPHYLLINE is: 200 mg orally every 6 hours, or 400 mg orally every 8-12 hours; maximum 600 mg per dose.. The standard adult dose of AEROLATE SR is: 400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXTRIPHYLLINE and AEROLATE SR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXTRIPHYLLINE is classified as Category C. Pregnancy Category C. No well-controlled studies in humans. Animal studies have shown adverse effects (fetal resorption, skeletal anomalies) at high doses. Risk cannot be ruled out. AEROLATE SR is classified as Category C. Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.